13F Holdings
中文EN

IBO IMPACT BIOMEDICAL INC.

Pharmaceutical Preparations · NYSE · SEC CIK 1834105 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY103.7%
TTM EPS YoY184.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-12,655.3%
Net margin4,247.4%
FCF margin—
EBITDA margin-9,657.9%

Returns

ROE—
ROA9.3%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets18.6%
Debt / equity0.00x
Current ratio0.04x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.07x
Accruals ratio8.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$32,000——$50,000
Cost of revenue$424,000———
Gross profit-$392,000———
R&D expense$340,000$278,000$1.69M$1.23M
SG&A expense$873,000$718,000$315,000$325,000
Operating income-$4.28M-$28.75M-$4.03M-$3.40M
Interest expense$793,000$1.06M$444,000$462,000
Pretax income-$14.45M-$24.74M-$4.41M-$7.88M
Income tax-$2.58M$33,000—-$621,000
Net income-$11.84M-$24.71M-$4.34M-$7.25M
EBITDA-$3.14M-$27.63M-$2.91M-$2.29M
EPS (basic)-0.38-2.30-0.07-0.10
EPS (diluted)-0.38-2.30-0.07-0.10
Balance sheet
Cash & equivalents$3,000$2.00M$1,000$2,000
Receivables$5,000$201,000$0—
Inventory$63,000———
Current assets$411,000$2.45M$332,000$122,000
PP&E, net—$17,000$287,000$276,000
Goodwill—$25.09M$25.09M$25.09M
Intangibles$16.99M$17.81M$18.92M$20.03M
Total assets$17.41M$20.29M$44.63M$46.50M
Current liabilities$1.16M$9.79M$13.14M$10.59M
Total liabilities$1.85M$13.05M$16.37M$13.83M
Shareholders' equity$12.31M$4.26M$25.22M$29.56M
Shares outstanding8.29M11.50M10.00M70.50M
Cash flow statement
Operating cash flow-$1.89M-$2.85M-$2.85M-$2.24M
Investing cash flow$3,000$2,000-$15,000-$349,000
Financing cash flow-$109,000$4.85M$2.87M$2.55M
Depreciation & amortization$1.15M$1.12M$1.12M$1.11M
Stock-based compensation$13,000$19,000——

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.